Supernus Pharmaceuticals (SUPN) Issues Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN) announced its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $0.52 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.09, Briefing.com reports. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. The company had revenue of $102.99 million for the quarter, compared to the consensus estimate of $100.75 million. During the same period in the prior year, the firm posted $0.29 EPS. The company’s quarterly revenue was up 28.1% compared to the same quarter last year.

Shares of NASDAQ:SUPN traded up $4.38 during trading hours on Wednesday, reaching $46.03. The stock had a trading volume of 34,268 shares, compared to its average volume of 480,952. Supernus Pharmaceuticals has a 1 year low of $33.30 and a 1 year high of $61.25. The company has a current ratio of 2.74, a quick ratio of 2.54 and a debt-to-equity ratio of 0.82. The company has a market cap of $2.43 billion, a PE ratio of 36.21 and a beta of 0.92.

Several large investors have recently made changes to their positions in SUPN. Glenmede Trust Co. NA grew its position in shares of Supernus Pharmaceuticals by 3.2% in the 2nd quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock valued at $39,070,000 after buying an additional 20,012 shares during the last quarter. Cynosure Advisors LLC grew its position in shares of Supernus Pharmaceuticals by 55.0% in the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 2,930 shares during the last quarter. SevenBridge Financial Group LLC purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $113,000. First Republic Investment Management Inc. grew its position in shares of Supernus Pharmaceuticals by 10.3% in the 2nd quarter. First Republic Investment Management Inc. now owns 12,572 shares of the specialty pharmaceutical company’s stock valued at $753,000 after buying an additional 1,179 shares during the last quarter. Finally, OppenheimerFunds Inc. grew its position in shares of Supernus Pharmaceuticals by 12.2% in the 2nd quarter. OppenheimerFunds Inc. now owns 305,402 shares of the specialty pharmaceutical company’s stock valued at $18,278,000 after buying an additional 33,092 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

A number of brokerages have commented on SUPN. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. Piper Jaffray Companies reissued a “hold” rating and issued a $46.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, July 25th. Cantor Fitzgerald reissued a “buy” rating and issued a $56.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday, September 14th. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 12th. Finally, ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $54.78.

WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/07/supernus-pharmaceuticals-supn-issues-earnings-results.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Article: Reverse Stock Split

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply